Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Toronto
$105,000.00
Variation in nicotine/nitrosamine pharmacology alters smoking behaviours and lung cancer risk: A genetic association and biomarker study
EF 2011-12
Résumé
Smoking is the leading risk factor for lung cancer, but we cannot easily predict which smokers will develop cancer. The risk of lung cancer is influenced by how the body reacts to chemicals in cigarette smoke part of which is driven by our genetics. The metabolic enzyme, CYP2A6, and the nicotinic receptor gene cluster, CHRNA5-CHRNA3-CHRNB4, interact with the addictive chemical in cigarette smoke, nicotine, and interact with nitrosamines, which are potent lung carcinogens. Variation in the CYP2A6 and CHRNA5-CHRNA3-CHRNB4 genes affects the number of cigarettes smoked per day and lung cancer risk, but the combined impact of having variation in both genes is unknown. We found that variation in both CYP2A6 and CHRNA5-CHRNA3-CHRNB4 combined to further increase the number of cigarettes smoked per day and the risk of lung cancer. We also found that the association of CYP2A6 and CHRNA5-CHRNA3-CHRNB4 with lung cancer risk was especially strong in individuals smoking less than 20 cigarettes per day. Our study was in European American smokers. We plan to extend our findings to African American smokers, who are at a higher risk of lung cancer despite smoking fewer cigarettes per day. We will also investigate another nicotine and nitrosamine metabolizing gene, CYP2B6, to increase our ability to predict whether a smoker will develop lung cancer. To gain insight into how variation in these genes affects smoking behaviours and lung cancer risk, we will quantify the amount of nicotine and nitrosamines in smokers. By identifying smokers at increased risk of lung cancer, our findings can be used to target at-risk smokers for smoking cessation programs and other disease prevention strategies. By understanding the genetic influences on smoking behaviours and lung cancer risk, our findings will also guide new treatment strategies for smoking cessation and for lung cancer. This genetic approach can be applied to characterize the risk for other diseases attributable to smoking.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
257566
Name
Wassenaar Catherine A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Variation in nicotine/nitrosamine pharmacology alters smoking behaviours and lung cancer risk: A genetic association and biomarker study
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Genetic Association Study; Genetic Variation In Chrna5-Chrna3-Chrnb4; Genetic Variation In Cyp2a6; Genetic Variation In Cyp2b6; Genetics Of Lung Cancer Risk; Genetics Of Smoking Behaviour; Nicotine And Nitrosamine Pharmacology; Smoking Biomarker Study
Abstract
Smoking is the leading risk factor for lung cancer, but we cannot easily predict which smokers will develop cancer. The risk of lung cancer is influenced by how the body reacts to chemicals in cigarette smoke part of which is driven by our genetics. The metabolic enzyme, CYP2A6, and the nicotinic receptor gene cluster, CHRNA5-CHRNA3-CHRNB4, interact with the addictive chemical in cigarette smoke, nicotine, and interact with nitrosamines, which are potent lung carcinogens. Variation in the CYP2A6 and CHRNA5-CHRNA3-CHRNB4 genes affects the number of cigarettes smoked per day and lung cancer risk, but the combined impact of having variation in both genes is unknown. We found that variation in both CYP2A6 and CHRNA5-CHRNA3-CHRNB4 combined to further increase the number of cigarettes smoked per day and the risk of lung cancer. We also found that the association of CYP2A6 and CHRNA5-CHRNA3-CHRNB4 with lung cancer risk was especially strong in individuals smoking less than 20 cigarettes per day. Our study was in European American smokers. We plan to extend our findings to African American smokers, who are at a higher risk of lung cancer despite smoking fewer cigarettes per day. We will also investigate another nicotine and nitrosamine metabolizing gene, CYP2B6, to increase our ability to predict whether a smoker will develop lung cancer. To gain insight into how variation in these genes affects smoking behaviours and lung cancer risk, we will quantify the amount of nicotine and nitrosamines in smokers. By identifying smokers at increased risk of lung cancer, our findings can be used to target at-risk smokers for smoking cessation programs and other disease prevention strategies. By understanding the genetic influences on smoking behaviours and lung cancer risk, our findings will also guide new treatment strategies for smoking cessation and for lung cancer. This genetic approach can be applied to characterize the risk for other diseases attributable to smoking.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wassenaar, Catherine A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~